Welcome to our dedicated page for AngioDynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on AngioDynamics stock.
Founded in 1988 in Queensbury, N.Y., U.S., AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of innovative medical devices that serve interventional radiologists, nephrologists, and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. The company's product portfolio includes market-leading systems such as the NanoKnife® system, radiofrequency ablation devices, and a variety of vascular access, angiographic, dialysis, angioplasty, and embolization products.
AngioDynamics has a strong track record of developing and bringing new technologies to market, maintaining a dynamic presence in the high-growth medical device industry. Recently, the company reported net sales of $78.7 million for the first quarter of fiscal year 2024, including a 13.3% increase in Med Tech net sales driven by the NanoKnife platform. AngioDynamics also completed the sale of its Dialysis and BioSentry Biopsy Tract Sealant System businesses, significantly enhancing its financial flexibility.
In addition to financial growth, AngioDynamics continues to innovate with significant developments such as the APEX-AV study, aimed at evaluating the safety and efficacy of the AlphaVac F1885 System for treating acute pulmonary embolism. The company’s AlphaVac F1885 System has recently received FDA clearance for the treatment of pulmonary embolism, a significant milestone that expands its indication in critical medical scenarios.
With ongoing plans to transition to a fully outsourced manufacturing model and recent divestitures to streamline its portfolio, AngioDynamics is well-positioned to focus on its core strengths and drive long-term profitability. The company's net sales are projected to be between $328 to $333 million for fiscal year 2024, with an anticipated improved gross margin and reduced adjusted loss per share.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q3 of fiscal year 2023 on
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology leader, announced participation in three investor conferences in March 2023. The Raymond James Institutional Investors Conference will be held on
AngioDynamics (ANGO) reported a strong Q2 FY2023, with net sales of $85.4 million, a 9.1% increase year-over-year. Med Tech sales surged 29.7% to $24.5 million, driven by Auryon and NanoKnife products. However, the company posted a GAAP loss per share of $0.21, unchanged from the prior year. Gross margin increased to 52.8%, despite macroeconomic pressures like labor shortages. For H1 FY2023, net sales rose 7.5% to $167 million. AngioDynamics reaffirmed its FY2023 guidance for net sales between $342 million and $348 million.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that Jim Clemmer, President and CEO, and Stephen Trowbridge, CFO, will present at the J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023, at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. This presentation focuses on AngioDynamics' commitment to transforming medical technology aimed at restoring vascular health and enhancing cancer treatment options. A live webcast will be available on the company's website, with a replay following the event.
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its financial results for Q2 of fiscal year 2023 on January 5, 2023, before the market opens. A conference call with management will be held at 8:00 a.m. ET to discuss these results. Investors can participate by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and using the passcode 13734978. The call will also be webcast on the AngioDynamics website, with a replay available shortly after the call concludes.
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology leader, announced that President & CEO Jim Clemmer and CFO Stephen Trowbridge will present at the Piper Sandler 34th Annual Healthcare Conference at 10:10 a.m. ET on November 30, 2022. The presentation will focus on the company's mission to enhance cancer treatment and restore healthy blood flow. Interested parties can access the live webcast through the Investors section of AngioDynamics' website, with a replay available post-event.
AngioDynamics (NASDAQ: ANGO) announced the enrollment of the first patient in the APEX-AV Study, evaluating the AlphaVac MMA F1885 System for treating acute intermediate-risk pulmonary embolism (PE). Conducted at 20 U.S. hospital sites, the study aims to assess the device's efficacy and safety. Key endpoints include RV/LV ratio reduction and the rate of major adverse events within 48 hours. This trial, in partnership with The PERT Consortium and Viz.ai, aims to improve PE care using advanced AI recruitment strategies.
AngioDynamics, a medical technology company, reported net sales of $81.5 million for the first quarter of fiscal 2023, marking a 5.9% increase from the prior year. Med Tech sales rose by 29.6% to $22.8 million, driven by solid performances from the Auryon and thrombectomy platforms. However, Med Device sales declined by 1.1% to $58.7 million. The company experienced a gross margin decrease to 51.9% and reported a net loss of $13.0 million or $0.33 per share. Fiscal year 2023 guidance is reaffirmed, expecting net sales between $342 million and $348 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its first quarter fiscal year 2023 financial results on October 6, 2022, before market open. Management will host a conference call at 8:00 a.m. ET the same day to discuss the results. Investors can join the conference call by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international), using passcode 13732702. The call will be webcast on AngioDynamics' website, with a replay available shortly after the call.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that Executive Vice President and CFO, Stephen Trowbridge, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 2:00 p.m. ET. Investors can access a live webcast of the presentation on AngioDynamics' website, with a replay available afterward. The company focuses on innovative medical technologies aimed at restoring blood flow, enhancing cancer treatment options, and improving patient quality of life. More information is available at www.angiodynamics.com.
FAQ
What is the current stock price of AngioDynamics (ANGO)?
What is the market cap of AngioDynamics (ANGO)?
What does AngioDynamics, Inc. specialize in?
What are some recent achievements of AngioDynamics, Inc.?
What is the AlphaVac F1885 System?
What financial performance did AngioDynamics report for the first quarter of fiscal year 2024?
What are AngioDynamics' future plans for manufacturing?
Where does AngioDynamics generate the majority of its revenue?
What is the NanoKnife® system?
How does AngioDynamics plan to enhance its focus on core strengths?
What is the APEX-AV study?
How does AngioDynamics contribute to the medical device industry?
